Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

Longbio Pharma

Status and phase: Enrolling; Phase 2

Conditions: Allergic Asthma

Treatments: Biological: LP-003 Injection; Biological: Placebo; Biological: Omalizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT07342803

P10-LP003-05

Details and patient eligibility

About

This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent allergic asthma.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥ 18 years and ≤ 75 years, no gender restriction;
2. Body weight ≥ 40 kg;
3. Diagnosed with bronchial asthma for at least 1 year according to the "Guidelines for Prevention and Treatment of Bronchial Asthma (2020 Edition)", and diagnosed with allergic asthma according to the "Chinese Guidelines for the Diagnosis and Treatment of Allergic Asthma (2019 Edition)" ; At least 1 asthma exacerbation in the year prior to screening (referring to GINA and Chinese guidelines, asthma exacerbation is defined as worsening of asthma symptoms requiring systemic glucocorticoid treatment for at least 3 days, and/or multiplying the dose of inhaled glucocorticoids for at least 3 days);
4. Positive bronchial dilation test within 24 months prior to screening or at the time of screening;
5. Subjects with at least one positive skin prick test or positive serum specific IgE test result for a relevant allergen within 12 months prior to randomization;
6. Subjects who have received medium to high dose inhaled corticosteroids (ICS) treatment for at least 8 weeks prior to screening (fluticasone propionate >250 μg/day or equivalent dose of ICS, not exceeding fluticasone propionate 2000 μg/day or equivalent dose of ICS, as per the "Guidelines for Prevention and Treatment of Bronchial Asthma (2020 Edition)"), have maintained stable use for 4 weeks before randomization, with asthma remaining partially controlled or uncontrolled (defined as ACT score ≤ 19);
7. Combined with at least one other asthma control medication (long-acting β2 receptor agonists (LABA), long-acting muscarinic antagonists (LAMA), leukotriene receptor antagonists (LTRA), and sustained-release theophylline treatment) and stable use for 4 weeks before randomization ;
8. At screening, 40% < FEV1 < 80% of predicted value;
9. Subjects who have no plans for pregnancy and agree to take effective contraceptive measures during the trial and for 6 months after the last dose of study treatment;
10. Subjects who voluntarily sign the ICF, are able to understand and correctly fill out the assessment form, correctly use the PEF device and record the patient diary card, and attend follow-up visits as scheduled.Male or female, aged 18 to 75 years.

Exclusion criteria

1. Allergic to the investigational product and its excipients or Xolair® ;
2. Coexisting diseases other than asthma that may affect lung function, such as chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and bronchiectasis, which, in the investigator's judgment, may place the subject at inappropriate risk or affect the assessment of study results;
3. Patients who have severe or uncontrolled diseases of the liver, kidneys, gastrointestinal tract, cardiovascular and cerebrovascular systems, hematopoietic system, urogenital system, endocrine system, nervous system, immune system, etc.;
4. Clinically significant infection history within 4 weeks prior to randomization, as assessed by the investigator, affecting patient evaluation;
5. Major surgery within 4 weeks prior to randomization or planned surgical procedures during the study period, or treatments that the investigator believes may affect patient evaluation;
6. Known parasitic infection within 6 months prior to randomization;
7. History of malignancy diagnosed within 5 years prior to screening;
8. Clinically significant abnormalities in laboratory tests during the screening period and baseline, deemed unsuitable for participation by the investigator ;
9. Positive test for human immunodeficiency virus (HIV) antibodies at screening, or positive for treponema pallidum antibodies (except RPR or TRUST negative), or positive for hepatitis B surface antigen (except HBV-DNA below the detection limit of the site), or positive for hepatitis B core antibody (except HBV-DNA below the detection limit of the site), or positive for hepatitis C virus (HCV) antibodies (except HCV RNA below the detection limit of the site);
10. Still smoking or having quit smoking for less than 6 months at screening, or a history of smoking ≥10 pack-years [Smoking Index (pack-years) = daily smoking amount (packs) × smoking duration (years), 1 pack = 20 cigarettes];
11. Used biological agents such as monoclonal antibodies, including investigational biological agents, within 3 months prior to screening or within 5 half-lives of the drug (whichever is longer);
12. Received systemic immunosuppressants or systemic glucocorticoids (dose equivalent to prednisone >10 mg/day) for inflammatory or autoimmune diseases (such as rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, etc.) within 8 weeks prior to screening or within 5 half-lives of the drug (whichever is longer);
13. Specific allergen immunotherapy conducted within 3 months prior to screening;
14. Live (attenuated) virus/bacterial vaccines administered or intravenous immunoglobulin used within 4 weeks prior to screening;
15. Participation in other drug clinical trials within 3 months or 5 half-lives of the drug (whichever is longer) prior to screening;
16. History of drug abuse, substance abuse, and/or excessive alcohol consumption within 1 year prior to screening;
17. Pregnant or breastfeeding women;
18. Any other condition that makes the subject unsuitable for participation in the trial as assessed by the investigator.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

200 participants in 5 patient groups, including a placebo group

LP-003 150 mg group

Experimental group

Description:

Participants received subcutaneous injections of LP-003 or Placebo every 4 weeks.

Treatment:

Biological: Placebo

Biological: LP-003 Injection

LP-003 300 mg group

Experimental group

Description:

Participants received subcutaneous injections of LP-003 or Placebo every 4 weeks.

Treatment:

Biological: Placebo

Biological: LP-003 Injection

LP-003 450 mg group

Experimental group

Description:

Participants received subcutaneous injections of LP-003 or Placebo every 4 weeks.

Treatment:

Biological: Placebo

Biological: LP-003 Injection

Omalizumab group

Active Comparator group

Description:

Participants received subcutaneous injection of Omalizumab every 4 weeks; the dose was determined by baseline IgE level and body weight, with a maximum dose 600 mg.

Treatment:

Biological: Omalizumab

Placebo group

Placebo Comparator group

Description:

Participants received subcutaneous injection of Placebo every 4 weeks.

Treatment:

Biological: Placebo